Erdotin (erdosteine) is a presciption mucolytica, which exerts its effect via an active metabolite that causes a decreased viscosity of sputum and an increased mucocilliary clearance. Registered as expectorating and for the treatment of acute exacerbations of chronic bronchitis in adults as well as for the treatment of lower respiratory infections in children above the age of 2 years in 7 to 10 days.
The effect is documented in studies with simultaneous treatment with antibiotics, which does not meet Danish guidelines. Hence, the results cannot directly be applied to Danish conditions. A single long-term study (8 months) suggests a preventive effect of erdosteine on the frequency of acute exacerbations of COPD and on the progression of reduced pulmonary function.
According to current guidelines on the treatment of COPD, mucolytica is recommended for symptomatical use as a supplement to other treatment with beta-2-agonist and/or local steroids, if any. The cost of treatment is DKK 9-12 per day. No general reimbursement has been granted for the treatment.
Erdotin was marketed on March 28, 2005.
Last modification: 29 November 2005